Immunotherapy of Sepsis

References

1. Roberts FJ, Geere IW, Coldman A. A three-year study of positive blood cultures, with emphasis on prognosis. J Infect Dis 1991; 13:34–46
   [Google Scholar]
2. Ziegler EJ, Fisher CJ Jr, Strung CL et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin—a randomized, double-blind, placebo-controlled trial. N Engl J Med 1991; 324:429–36
   [Google Scholar]
3. Glauser MP, Zanetti G, Baumgartner J-D, Cohen J. Septic shock: pathogenesis. Lancet 1992; 338:732–6
   [Google Scholar]
4. Tracey KJ, Fong Y, Hesse DG et al. Anti-cachectin/tumour necrosis factor antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330:662–4
   [Google Scholar]
5. Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987; i:355–7
   [Google Scholar]
6. Ziegler EJ, McCutchan JA, Fierer J et al. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli . N Engl J Med 1982; 307:1225–30
   [Google Scholar]
7. Baumgartner JD, Glauser MP. Controversies in the use of passive immunotherapy for bacterial infections in the critically ill patient. Rev Infect Dis 1987; 9:194–205
   [Google Scholar]
8. Baumgartner JD, Glauser MP, McCutchan JA et al. Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet 1985; 2:59–63
   [Google Scholar]
9. The Intravenous Immunoglobulin Study Group. Prophylactic administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection N Engl J Med 1992; 327234–40
   [Google Scholar]
10. Warren HS, Danner RL, Munford RS. Sounding aboard: anti endotoxin antibodies. N Engl J Med 1992; 326:1153–7
    [Google Scholar]
11. Siegel JP, Stein KE, Zoon KC. Anti-endotoxin monoclonal antibodies (letter). N Engl J Med 1992; 327:890–1
    [Google Scholar]
12. Baumgartner JD, Heumann D, Gerain J, Weinbreck P, Grau GE, Glauser MP. Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumour necrosis a and interleukin 6. J Exp Med 1990; 171:889–96
    [Google Scholar]
13. Tonoli M, Davies KA, Appelmelk BJ, Walport MJ, Cohen J. In vitro binding of human monoclonal anti-lipid A antibody (HA-1A) to gram-negative bacteria. Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy 1992 Abstract No. 10
    [Google Scholar]
14. Wenzel R, Bone R, Fein A et al. Results of a second double blind randomized controlled trial of anti-endotoxin antibody E5 in gram-negative sepsis. Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy 1991 Abstract No. 1170
    [Google Scholar]
15. Echtenacher B, Falk W, Mannel DN, Krammer PH. Requirement of endogenous tumour necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 1990; 145:3762–6
    [Google Scholar]
16. Opal SM, Fisher CJ, Slotman GJ et al. The phase II Interleukin-1 receptor antagonist (IL-lra) sepsis syndrome trial: analysis of clinical, cytokine, and microbial features with outcome. Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy 1992 Abstract No. 1570
    [Google Scholar]
17. Nadel S, Klein N, Heyderman R, Levin M. Endotoxin antibody for sepsis in infants. Lancet 1992; 339:678
    [Google Scholar]